Exelixis, Inc. or Opthea Limited: Who Invests More in Innovation?

Exelixis vs. Opthea: A Decade of R&D Investment

__timestampExelixis, Inc.Opthea Limited
Wednesday, January 1, 20141891010003401685
Thursday, January 1, 2015963510004284228
Friday, January 1, 2016959670003581295
Sunday, January 1, 20171121710004838300
Monday, January 1, 201818225700024891534
Tuesday, January 1, 201933696400031347891
Wednesday, January 1, 202054785100017480747
Friday, January 1, 202169371600034710152
Saturday, January 1, 2022891813000108459978
Sunday, January 1, 20231044071000181563523
Monday, January 1, 2024910408000176326321
Loading chart...

Unleashing the power of data

Innovation Investment: Exelixis, Inc. vs. Opthea Limited

In the competitive world of biotechnology, innovation is key. Exelixis, Inc. and Opthea Limited are two companies that have consistently invested in research and development (R&D) to drive their growth. From 2014 to 2023, Exelixis, Inc. has shown a remarkable commitment to innovation, with R&D expenses increasing by over 450%. In contrast, Opthea Limited's R&D spending, while growing, has been more modest, with a 530% increase over the same period.

Exelixis, Inc. reached its peak R&D investment in 2023, spending nearly 1.04 billion dollars, a significant leap from its 2014 expenditure. Opthea Limited, on the other hand, saw its highest R&D spending in 2023 as well, with approximately 182 million dollars. This data highlights the strategic focus of both companies on innovation, albeit at different scales.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025